Literature DB >> 22902266

Impact of pulmonary hemodynamics on 6-min walk test in idiopathic pulmonary fibrosis.

Omar A Minai1, Jose F Santacruz, Joan M Alster, Marie M Budev, K McCarthy.   

Abstract

OBJECTIVES: Pulmonary hypertension (PH) has been associated with decreased functional capacity in patients with advanced idiopathic pulmonary fibrosis (IPF). We aimed to evaluate the true impact of altered pulmonary hemodynamics on functional capacity in a cohort of patients with IPF.
METHODS: Between January 1990 and December 2007, 124 patients [73M/51F; 111 Caucasians] with IPF underwent right heart catheterization and 6-min walk test (6MWT). Pulmonary arterial hypertension (PAH) was defined as mPAP≥25 and pulmonary artery occlusion pressure (PAOP)≤15mmHg, and Pre-PH as mPAP>20 and <25mmHg with PAOP<15mmHg. Demographic, hemodynamic, spirometric, and 6MWT data were collected.
RESULTS: Fifty four (44%) patients had PH. There were no significant differences between the PH and the non-PH groups in measures of pulmonary function other than PaO(2). Patients with PH and PAH had significantly lower 6-min walk distance (6MWD) (p=0.008 and p=0.03 respectively) and distance saturation product (DSP) (p=0.002 and p=0.006 respectively) compared to non-PH patients. Mean pulmonary arterial pressure (mPAP) was the best predictor of 6MWD by multivariate analysis (p=0.0006). Increasing mPAP was associated with a statistically significant decline in 6MWD (p=0.02) and DSP (p=0.01). Patients with 'Pre-PH' had lower 6MWD compared to patients with mPAP≤20mmHg (p=0.07).
CONCLUSIONS: Relative to measures of pulmonary function and hypoxia, altered pulmonary hemodynamics had a greater impact on 6MWD in patients with IPF. Higher mPAP was associated with more significant exercise impairment. Mild abnormalities in pulmonary hemodynamics (so called 'Pre-PH') were associated with reduced 6MWD.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22902266     DOI: 10.1016/j.rmed.2012.07.013

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  24 in total

Review 1.  Classification and diagnosis of pulmonary hypertension.

Authors:  Hector R Cajigas; Rana Awdish
Journal:  Heart Fail Rev       Date:  2016-05       Impact factor: 4.214

2.  Survival in pulmonary hypertension due to chronic lung disease: Influence of low diffusion capacity of the lungs for carbon monoxide.

Authors:  Lauren Rose; Kurt W Prins; Stephen L Archer; Marc Pritzker; E Kenneth Weir; Jeffrey R Misialek; Thenappan Thenappan
Journal:  J Heart Lung Transplant       Date:  2018-09-14       Impact factor: 10.247

3.  Multi-dimensional Assessment of IPF Across a Wide Range of Disease Severity.

Authors:  Hana Serajeddini; Paola Rogliani; Marco Mura
Journal:  Lung       Date:  2018-08-27       Impact factor: 2.584

Review 4.  Group 3 Pulmonary Hypertension: From Bench to Bedside.

Authors:  Navneet Singh; Peter Dorfmüller; Oksana A Shlobin; Corey E Ventetuolo
Journal:  Circ Res       Date:  2022-04-28       Impact factor: 23.213

Review 5.  New perspectives on management of idiopathic pulmonary fibrosis.

Authors:  Silvia Puglisi; Sebastiano Emanuele Torrisi; Virginia Vindigni; Riccardo Giuliano; Stefano Palmucci; Massimiliano Mulè; Carlo Vancheri
Journal:  Ther Adv Chronic Dis       Date:  2016-02-01       Impact factor: 5.091

6.  Can a Six-Minute Walk Distance Predict Right Ventricular Dysfunction in Patients with Diffuse Parenchymal Lung Disease and Pulmonary Hypertension?

Authors:  Kamonpun Ussavarungsi; Augustine S Lee; Charles D Burger
Journal:  Oman Med J       Date:  2016-09

7.  Determinants of 6-minute walk distance in patients with idiopathic pulmonary fibrosis undergoing lung transplant evaluation.

Authors:  Mary K Porteous; Belinda N Rivera-Lebron; Maryl Kreider; James Lee; Steven M Kawut
Journal:  Pulm Circ       Date:  2016-03       Impact factor: 3.017

8.  Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia.

Authors:  Tamera J Corte; Gregory J Keir; Konstantinos Dimopoulos; Luke Howard; Paul A Corris; Lisa Parfitt; Claire Foley; Monica Yanez-Lopez; Daphne Babalis; Philip Marino; Toby M Maher; Elizabeth A Renzoni; Lisa Spencer; Charlie A Elliot; Surinder S Birring; Katherine O'Reilly; Michael A Gatzoulis; Athol U Wells; Stephen J Wort
Journal:  Am J Respir Crit Care Med       Date:  2014-07-15       Impact factor: 21.405

9.  Pulmonary hypertension in patients with idiopathic pulmonary fibrosis - the predictive value of exercise capacity and gas exchange efficiency.

Authors:  Sven Gläser; Anne Obst; Beate Koch; Beate Henkel; Anita Grieger; Stephan B Felix; Michael Halank; Leonhard Bruch; Tom Bollmann; Christian Warnke; Christoph Schäper; Ralf Ewert
Journal:  PLoS One       Date:  2013-06-20       Impact factor: 3.240

Review 10.  Managing comorbidities in idiopathic pulmonary fibrosis.

Authors:  Blair G Fulton; Christopher J Ryerson
Journal:  Int J Gen Med       Date:  2015-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.